FORM PTO-1390 (Modified) (REV 5-93) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 081356/0156

		U.S. APPLICATION NO. (If known, see 37 CFR 1.5): Unassigned 09/720970
INTERNATIONAL APPLICATION NO. PCT/JP99/03563	INTERNATIONAL FILING DATE July 1, 1999	PRIORITY DATE CLAIMED July 8, 1998

TITLE OF INVENTION
POWDERY PREPARATION FOR MUCOSAL ADMINISTRATION CONTAINING POLYMERIC MEDICINE

APPLICANT(S) FOR DO/EO/US
Hideaki Nomura, Yosuke UEKI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   - ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   - ☒ has been transmitted by the International Bureau.
   - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   - ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   - ☐ have been transmitted by the International Bureau.
   - ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   - ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

528 Rec'd PCT/PTO 03 JAN 2001

U.S. APPLICATION NO (If known, see 37 C.F.R. 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
Unassigned 09/720970	PCT/JP99/03563	081356/0156

17. ☒ The following fees are submitted:

	CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO $860.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) $690.00		
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2) $710.00		
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO $1,000.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) $100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$860.00	
Surcharge of $130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))		

Claims	Number Filed		Included in Basic Fee		Extra Claims		Rate		
Total Claims	12	-	20	=	0	×	$18.00	$0.00	
Independent Claims	2	-	3	=	0	×	$80.00	$0.00	
Multiple dependent claim(s) (if applicable)							$270.00		
TOTAL OF ABOVE CALCULATIONS =								$860.00	
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).								$0.00	
SUBTOTAL =								$860.00	
Processing fee of $130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f). +									
TOTAL NATIONAL FEE =								$860.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +								$40.00	
TOTAL FEES ENCLOSED =								$900.00	
							Amount to be: refunded	$	
							charged	$	

a. ☒ A check in the amount of $900.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 19-0741 in the amount of $0.00 to the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Foley & Lardner
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

SIGNATURE

NAME STEPHEN A. BENT

REGISTRATION NUMBER 29,768

Atty. Dkt. No. 081356/0156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hideaki Nomura et al

Title: POWDERY PREPARATION FOR MUCOSAL ADMINISTRATION CONTAINING POLYMERIC MEDICINE

Appl. No.: Unassigned

Filing Date: 12/28/2000

Examiner: Unassigned

Art Unit: Unassigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicants respectfully request that the following amendment be entered into the application:

In the Claims:

Claim 9 line 1, please delete "any one of claims 1-8" and insert --claim 1--.

REMARKS

Entry of the foregoing amendment prior to examination is respectfully requested.

Respectfully submitted,

Date January 3, 2001

By _____

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

DESCRIPTION

HIGH MOLECULAR WEIGHT MEDICINE-CONTAINING PREPARATION IN POWDER FORM FOR ADMINISTRATION THROUGH MUCOSA

Technical Field of the Invention

The present invention relates to a preparation for administration through mucosa, containing a medicine of high molecular weight as an active ingredient. More particularly, the invention relates to a preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer. In particular, the invention relates to a preparation in a powder form for administration through nasal mucosa.

Background Art

Currently, high molecular weight medicines are administered to patients by intravenous or subcutaneous injection. However, since the administration by injection is difficult to be performed by patients themselves and is accompanied with pain, administration through mucosa is desired as a simpler method than injection. Specific examples of administration through mucosa include administration through nasal mucosa, ocular mucosa, oral mucosa, pulmonary mucosa or vaginal mucosa; or through the mucosa of digestive tract such as gastric mucosa, small intestinal mucosa, large intestinal mucosa or rectal mucosa. Among all,

administration through nasal mucosa is attracting attention as a relatively simple administration method by which rapid absorption of medicines and positive effect can be achieved. However, the absorbability depends on the molecular weight of the medicine used. Although medicines with a molecular weight of 1,000 or less are absorbed relatively effectively, effective absorption of those medicines of larger molecular weights is difficult to achieve without some contrivance (C. McMartin et al., J. Pharm. Sci., 76 (7):535-540 (1987)). Thus, it has been difficult to achieve therapeutic effect by administration of high molecular weight medicines through nasal mucosa.

Means to improve the low absorbability of high molecular weight medicines include, methods in which a surfactant or a salt of bile acid is jointly used as an absorption promoting agent (S. Hirai et al., Int. J. Pharm., 9:173-184 (1981); Y. Maitani et al., Drug Design and Delivery, 1:65-70 (1986)); and methods in which cyclodextrin is jointly used as an absorption promoting agent (N.G.M. Schipper et al., J. Control Release, 21 (1):173-185 (1992); T. Irie et al., J. Inter. Pharm., 84:129-139 (1992)). However, it is apprehended that these absorption promoting agents may be harmful to nasal mucosa. Also known are methods in which a high molecular weight substance such as albumin, dextran or sodium hyaluronate is jointly used as an absorption promoting agent (T. Igawa et al., Chem. Pharm. Bull. 36(8):3055-3059 (1988); Japanese

Unexamined Patent Publication No. 6-65090; Japanese Unexamined Patent Publication No. 8-198772). However, these methods still cannot achieve sufficient absorption promoting effect and have difficulty in industrial production of such compositions. Thus, none of the above-mentioned methods has been put to practical use.

Japanese Unexamined Patent Publication No. 10-95738 discloses a preparation using fluorescein thiocyanate dextran (hereinafter referred to as "FITC-dextran"; molecular weight: 4,400) as a model drug (substance) of low absorbability. This preparation was obtained by adding FITC-dextran to physiological saline in which arginine, poly-arginine or a salt of poly-arginine was dissolved. When this preparation was administered to the nasal cavity mucosa of Wistar rats, higher FITC-dextran levels in blood were retained.

Japanese Unexamined Patent Publication No. 4-503508 discloses the administration into rat's nostrils of a preparation obtained by adding DEAE-dextran or chitosan to an insulin solution.

Although various methods as described above have been developed, a more effective and practical method is still required as a means to improve the low absorbability of high molecular weight medicines.

Under such circumstances, it is an object of the present invention to provide a preparation for administration through mucosa, in particular through nasal mucosa, which enables safe and effective

absorption of a high molecular weight medicine through mucosa. It is another object of the invention to provide a pharmaceutical composition in powder form which enables safe and effective absorption of a high molecular weight medicine by living bodies.

Disclosure of the Invention

As a result of intensive and extensive researches toward the development of those preparations which enable safe and effective absorption of a high molecular weight medicine through mucosa, the present inventors have found 1) that a cationic polymer promotes the absorption of a high molecular weight medicine through mucosa by expanding tight junctions of mucosal tissues; and 2) that combined use of a cationic polymer with a viscous polymer further enhances the absorption since the viscous polymer extends the residence time of the relevant preparation in mucosa. Thus, the present invention has been achieved. Also, the present inventors have found that, among cationic polymers, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate is superior to poly-L-arginine (which is also a cationic polymer) in absorption promoting effect.

The present invention provides a preparation in powder form for administration through mucosa, in particular for pernasal administration, comprising a medicine of high molecular weight and a cationic polymer. It is preferred that the powder form

preparation of the invention for administration through mucosa further comprise a viscous polymer. Specific examples of cationic polymers include copolymers of aminoalkylmethacrylate, polyvinyl acetal diethylaminoacetate and poly-L-arginine. Copolymers of aminoalkylmethacrylate and polyvinyl acetal diethylaminoacetate are preferable. As a viscous polymer, hydroxypropylmethyl cellulose may be mentioned. A medicine of high molecular weight may be selected from the group consisting of bioactive peptides and proteins, antibodies, vaccines, and antigens. The preparation of the invention is especially effective for the administration of granulocyte colony-stimulating factor, insulin, erythropoietin, growth hormone or influenza antigens through mucosa, in particular through nasal mucosa.

The present invention also provides a pharmaceutical composition in powder form, comprising a medicine of high molecular weight and a cationic polymer. In the pharmaceutical composition of the invention in powder form, a medicine of high molecular weight may be selected from the group consisting of bioactive peptides and proteins, antibodies, vaccines, and antigens. The pharmaceutical composition of the invention in powder form is especially effective for the administration of granulocyte colony-stimulating factor, insulin, erythropoietin, growth hormone or influenza antigens.

Hereinbelow, the present invention will be

described in detail.

In one embodiment of the invention, the powder form preparation of the invention for administration through mucosa is obtained by adding to a medicine of high molecular weight an excipient (e.g. saccharides) and a cationic polymer and optionally a viscous polymer and, if necessary, appropriate additives and then freeze-drying or spray-drying the resultant mixture.

"A medicine of high molecular weight" used in the invention refers to a bioactive peptide or protein; antibody, vaccine, antigen or the like. Specific examples include the following substances, which are not intended to limit the present invention: calcitonin, insulin, proinsulin, vasopressin, desmopressin, luteinizing hormone, luteinizing hormone-releasing hormone, somatostatin, prolactin, glucagon, gastrin, secretin, kallikrein, urokinase, neurotensin, enkephalin, kyotorphin, endorphin, endothelin, angiotensin, transferrin, atrial natriuretic polypeptide, epithelial cell growth factor, growth hormone, parathyroid hormone, interferons, interleukins, tumor necrosis factor, leukemia inhibitory factor, hematopoietic stem cell growth factor, erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage-stimulating factor, macrophage colony-stimulating factor, thrombopoietin, superoxide dismutase, tissue plasminogen activator, antithrombin, blood coagulation factors, anti-IgE antibodies, anti-IgA antibodies,

anti-tumor antibodies, antibodies to tumor necrosis factor, anti-interleukin antibodies, HIV-neutralizing antibodies, anti-platelet antibodies, anti-hepatitis virus antibodies, hepatitis vaccines, influenza vaccines (influenza antigens), pertussis vaccine, diphtheria vaccine, tetanus toxoids vaccine, peptides or proteins such as pollen from Japanese cedar or ragweed which may act as antigen, such peptides or proteins conjugated to haptens, and mixtures of such peptides, proteins or conjugates with adjuvants. It is easily presumed that the present invention will also improve the absorbability through mucosa, in particular through nasal mucosa, of medicines which have smaller molecular weights than the above enumerated high molecular weight medicines. Thus, it is believed that the application of the present invention to them will be also useful.

Examples of G-CSF which is one of the high molecular weight medicines that can be used in the present invention include a polypeptide with human G-CSF activity represented by the amino acid sequence of SEQ ID NO: 1, 2 or 3; and a glycoprotein composed of the above polypeptide and sugar chains added thereto. Further, G-CSF derivatives with G-CSF activity represented by the above-mentioned amino acid sequence which is partially modified (i.e. has substitution, deletion, insertion and/or addition) are also included in the G-CSF of the invention.

These G-CSFs may be extracted/separated/purified

from natural products, or they may be produced by transformants obtained by recombinant techniques and then isolated/purified. Examples of host cells for such transformation include E. coli and mammal cells (e.g. C127, CHO cells). Detailed methods for producing these G-CSFs are disclosed, for example, in Japanese Unexamined Patent Publication/PCT No. 63-500636 and Japanese Unexamined Patent Publication Nos. 62-236497, 62-236488 and 63-267292.

The content of a medicine of high molecular weight in the powder form preparation of the invention is usually 0.01 to 90% (w/w), preferably 0.1 to 50% (w/w).

"A cationic polymer" used in the invention refers to a polymer which has a cation charge in its monomer units forming a repetitive structure, or a polymer which has such a structure that it acquires a cation charge upon dissolution. The cationic polymer used in the invention may be any cationic polymer as long as it promotes the absorption of high molecular weight medicines through mucosa. Specifically, a copolymer of aminoalkylmethacrylate, polyvinyl acetal diethylaminoacetate, poly-L-arginine or the like may be used. A copolymer of aminoalkylmethacrylate is available from, for example, Rohm Pharma under the trade name Eudragit E or Eudragit RS. Eudragit E is a copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate with an average molecular weight of 150,000. Polyvinyl acetal diethylaminoacetate is available from, for example,

Sankyo Co., Ltd. under the trade name AEA. This is a polymer with an average molecular weight of 65,000 which is obtained by dehydrating polyvinyl alcohol and acetaldehyde to generate acetal and hydroxyl, and then attaching diethyl aminoacetate to a part of the acetal and hydroxyl by ester linkage. Poly-L-arginine is a polymer of L-arginine. Its average molecular weight is 1000 to 1,000,000. Preferably, this polymer has an average molecular weight of 12,100 to 92,000, more preferably 92,000. Poly-L-arginine is available from Sigma. The content of a cationic polymer in the powder form preparation of the invention for administration through mucosa is usually 0.1 to 90% (w/w), preferably 1 to 50% (w/w).

"A viscous polymer" used in the invention refers to a polymer which becomes viscous when dissolved or swollen. The viscous polymer used in the invention may be any viscous polymer as long as it increases the absorption of a medicine of high molecular weight when used in combination with a cationic polymer, as compared to the case when the cationic polymer is used alone. Specific examples of such viscous polymers include hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxyvinyl polymer, agar powder and gum arabic powder. The content of a viscous polymer in the powder form preparation of the invention for administration through mucosa is usually 0.1 to 90% (w/w), preferably 1 to 50% (w/w).

An excipient used in the invention is, typically,

a saccharide.

Specific examples of saccharides include xylitol, fructose, sorbitol, lactose, inositol, sucrose and mannitol. Other examples of excipients include starches, inorganic substances, organic acids and amino acids. As starches, corn starch, wheat starch, potato starch and the like may be enumerated. As inorganic substances, calcium phosphate, calcium hydrogenphosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, magnesium carbonate, sodium chloride, calcium sulfate and the like may be enumerated. As organic substances, succinic acid, tartaric acid, citric acid, fumaric acid, malic acid, gluconic acid, glucuronic acid, salts thereof, and the like may be enumerated. As amino acids, L-arginine, D,L-methionine, L-phenylalanine, L-glutamic acid and the like may be enumerated. The content of the excipient in the powder form preparation of the invention for administration through mucosa is usually 1 to 90% (w/w), preferably 5 to 80% (w/w).

If necessary, additives such as a lubricant may be used in the present invention. Specific examples of lubricants include magnesium stearate, stearic acid and talc. The content of the additives in the powder form preparation of the invention for administration through mucosa is usually 0.01 to 90% (w/w), preferably 0.05 to 50% (w/w).

Hereinbelow, a exemplary method for producing the powder form preparation of the invention for

administration through mucosa will be described briefly.

A buffer solution containing G-CSF is mixed with a buffer solution in which a cationic polymer, an excipient such as sucrose or mannitol and, optionally, a viscous polymer have been dissolved in advance. The resultant mixture is spray-dried to obtain a powder.

Necessary amounts of the resultant powder are weighed out and packed in capsules to obtain a preparation in powder form for administration through mucosa.

The thus prepared powder of the preparation for administration through mucosa is usually 0.1 to 500 μm, preferably 5 to 100 μm in particle size.

The powder of the preparation for administration through mucosa is easy to handle when it is packed in capsules. As a material for the capsule base, gelatin, hydroxypropylmethyl cellulose, methyl cellulose, starch or the like may be used. Glycerol, sorbitol, carrageenan, polyethylene glycol, gum arabic or the like may be added to the above material to increase plasticity.

Additionally, potassium chloride, sucrose, a coloring agent and titanium oxide may also be added.

The preparation of the invention in powder form for administration through mucosa may be applied to the mucous membrane of patients at the time of need or at an appropriate frequency. Specific examples of mucosa include nasal mucosa, ocular mucosa, oral mucosa, pulmonary mucosa, vaginal mucosa and mucous membranes

of digestive tract such as gastric mucosa, small intestinal mucosa, large intestinal mucosa and rectal mucosa. For example, when the preparation of the invention is administered through nasal mucosa, a capsule containing the powder form preparation is set in a small-sized sprayer (Publizer™). After a hole is made in the capsule, the nozzle of the sprayer is inserted into one of the nostrils of the patient. While he is breathing in through the nose, the patient presses the rubber ball of the sprayer to thereby spray the powder form preparation into the nasal cavity. A preparation of the invention containing granulocyte colony-stimulating factor as an active ingredient may be administered to patients 1 to 4 times a day such that the dose of the active ingredient is 1-500 μg/kg/day, preferably 5-100μg/kg/day. A preparation of the invention containing insulin as an active ingredient may be administered to patients 1 to 4 times a day such that the dose of the active ingredient is 0.1-100 U/kg/day, preferably 0.5-20 U/kg/day. A preparation of the invention containing erythropoietin as an active ingredient may be administered to patients 1 to 4 times a day such that the dose of the active ingredient is 50-50,000 IU/kg/day, preferably 200-8,000 IU/kg/day. A preparation of the invention containing growth hormone as an active ingredient may be administered to patients 1 to 4 times a day such that the dose of the active ingredient is 0.1-50 IU/kg/day, preferably 0.4-15 IU/kg/day. A preparation

of the invention containing an influenza antigen as an active ingredient may be administered to persons in need of such a preparation 1 to 4 times a day with an interval of 2-6 weeks such that the dose of the active ingredient is 0.5-200 CCA/kg/day, preferably 20-40 CCA/kg/day.

The present specification includes the contents of the specifications and the attached drawings of Japanese Patent Application Nos. 10-192722 and 11-81549 based on which the present application claims priority.

Best Modes for Carrying Out the Invention

Hereinbelow, the present invention will be described specifically with reference to the following Examples. However, the scope of the invention is not limited to these Examples.

The cationic polymers, sucrose, D-mannitol, hydroxypropylmethyl cellulose, sodium hyaluronate and components of buffer solutions dissolving them (buffer components) used in the following Examples and Comparative Examples are as described below.

Cationic polymers

Poly-L-arginine (Sigma)

Aminoalkylmethacrylate copolymer E (Rohm Pharma; Trade Name: Eud
ragit E100)

Polyvinyl acetal diethylaminoacetate (Sankyo Co., Ltd.; Trade Na
me: AEA)

Diethylaminoethyl (DEAE)-dextran (Fluka)

Chitosan (Chitosan 8B; manufactured by Katokichi Co., Ltd. and s
old by Funakoshi)

Sucrose (Kosakai Pharmaceutical; saccharose prepared according to the
Japanese Pharmacopoeia)

D-mannitol (Kao Corp.; Trade Name: Nikkyoku Mannitol Kao)

Hydroxypropylmethyl cellulose (Shin-Etsu Chemical; Trade Name: Metholo
se 60SH4000)

Sodium hyaluronate (Tokyo Kasei Organic Chemicals)

Buffer components

Citric acid (Oriental Pharmaceutical & Synthetic Chemical)

Phosphoric acid (Kokusan Kagaku)

The medicines of high molecular weight used in the following Examples are as described below.

The granulocyte colony-stimulating factor (G-CSF) used is a polypeptide having the amino acid sequence shown in SEQ ID NO: 1, produced by a transformed E. coli (see Japanese Unexamined Patent Publication/PCT No. 63-500636). The thus obtained G-CSF was concentrated, followed by buffer replacement to prepare a buffer solution ontaining G-CSF.

The insulin used is a commercial product (Boehringer Mannheim; recombinant human insulin; Mw =

ca. 5700).

The erythropoietin used is a commercial product (Kirin Brewery; recombinant human erythropoietin; Mw = ca. 30,000).

The growth hormone used is a commercial product (Chemicon; recombinant human growth hormone; Mw = ca. 22,000).

The influenza A antigen used is a commercial product (Chemicon).

<EXAMPLE 1>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and poly-L-arginine was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Poly-L-arginine	20% (w/w)
Sucrose	26% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 2>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and polyvinyl acetal diethylaminoacetate (AEA) was added.
The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration

having he following formula.

G-CSF	20% (w/w)
AEA	20% (w/w)
Sucrose	26% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 3>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	20% (w/w)
Sucrose	26% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 4>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	10% (w/w)

Sucrose	63% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 5>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	20% (w/w)
Sucrose	53% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 6>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	30% (w/w)
Sucrose	43% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 7>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	57% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 8>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	20% (w/w)
Sucrose	47% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 9>

To a buffer solution containing G-CSF, a buffer solution containing sucrose, aminoalkylmethacrylate

copolymer E (Eudragit E100) and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	20% (w/w)
HPMC	10% (w/w)
Sucrose	37% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 10>

To a buffer solution containing G-CSF, a buffer solution containing sucrose, aminoalkylmethacrylate copolymer E (Eudragit E100) and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Eudragit E100	20% (w/w)
HPMC	20% (w/w)
Sucrose	27% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 1>

To a buffer solution containing G-CSF, a buffer

solution containing sucrose was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Sucrose	46% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 2>

To a buffer solution containing G-CSF, a buffer solution containing sucrose and sodium hyaluronate was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	20% (w/w)
Sodium hyaluronate	20% (w/w)
Sucrose	26% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXPERIMENTAL EXAMPLE 1>

Male beagles were used in this experiment. The preparations from Example 1 and Comparative Example 1 were separately packed in gelatin capsules such that each capsule would give the dog 100 μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 2.5 cm in length bonded to its tip. Then, the

silicone tube portion was inserted into the nasal cavity of the dog through one of its nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood G-CSF levels were determined by ELISA (T. Ichikawa et al., Experimental Hematology 23: 192-195 (1955)). Table 1 shows the value of area under the blood G-CSF level vs time curve (AUC_G) for each preparation. The preparation of Example 1 containing poly-L-arginine as a cation polymer exhibited a higher AUC_G value than the preparation of Comparative Example 1 containing no high molecular weight substances. Thus, it was found that the addition of poly-L-arginine promotes the absorption of G-CSF through nasal mucosa.

Table 1.

Preparation administered	Comparative Ex.1	Example 1
AUC_G 0 $\rightarrow$32 hr ($\cdot$ hr $\cdot$ ml^{-1})	5.3	10.3

<EXPERIMENTAL EXAMPLE 2>

Male beagles were used in this experiment. The preparations from Comparative Examples 1 and 2 were separately packed in gelatin capsules such that each capsule would give the dog 100 μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube

about 2.5 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood G-CSF levels were determined by ELISA. Table 2 shows the value of area under the blood G-CSF level vs time curve (AUC_G) for each preparation. The preparation of Comparative Example 2 containing sodium hyaluronate (a non-cationic polymer) exhibited substantially the same AUC_G value as the preparation of Comparative Example 1 containing no high molecular weight substances. Thus, the addition of sodium hyaluronate showed little promotive effect on G-CSF absorption.

Table 2.

Preparation administered	Comparative Ex. 1	Comparative Ex. 2
AUC_G 0 $\rightarrow$32 hr ($ng \cdot hr \cdot ml^{-1}$)	4.8	4.6

<EXPERIMENTAL EXAMPLE 3>

Male beagles were used in this experiment. The preparations from Examples 1, 2 and 3 were separately packed in gelatin capsules such that each capsule would give the dog 100 μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in

length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Leukocyte counts in blood samples were determined with a micro-cell counter. Blood G-CSF levels were determined by ELISA. Table 3 shows the values of area under the increased leukocyte count vs time curve (AUC_W) and of area under the blood G-CSF level vs time curve (AUC_G) for the preparations tested. As a result, it was found that AEA and Eudragit E100 have a better absorption-promoting effect than poly-L-arginine.

Table 3.

Preparation administered	Example 1	Example 2	Example 3
AUC_W 0 →72 hr (count · hr · ml^{-1})	3083	5095	5707
AUC_G 0 →31 hr (ng · hr · ml^{-1})	13.4	73.0	44.4

<EXPERIMENTAL EXAMPLE 4>

Male beagles were used in this experiment. The preparations from Examples 4, 5, 6 and 7 were separately packed in gelatin capsules such that each capsule would give the dog 100μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube

about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Leukocyte counts in blood samples were determined with a micro-cell counter. Blood G-CSF levels were determined by ELISA. Table 4 shows the values of area under the increased leukocyte count vs time curve (AUC_W) and of area under the blood G-CSF level vs time curve (AUC_G) for the preparations tested. The effect of Eudragit E100 was retained in spite of various changes in its content.

Table 4.

Preparation Administered	Example 4	Example 5	Example 6	Example 7
AUC_W 0 →72 hr (count · hr · ml^{-1})	3475	4053	4138	4562
AUC_G 0 →31 hr (ng · hr · ml^{-1})	25.6	27.1	16.8	11.1

<EXPERIMENTAL EXAMPLE 5>

Male beagles were used in this experiment. The preparations from Examples 8, 9 and 10 were separately packed in gelatin capsules such that each capsule would give the dog 100 μg of G-CSF per kg of body weight. The gelatine capsule was mounted in Publizer™

(Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Leukocyte counts in blood samples were determined with a micro-cell counter. Blood G-CSF levels were determined by ELISA. Table 4 shows the values of area under the increased leukocyte count vs time curve (AUC_W) and of area under the blood G-CSF level vs time curve (AUC_G) for the preparations tested. As a result, it became evident that the addition of HPMC together with Eudragit E100 enhances the absorption promoting effect as compared to the addition of Eudragit alone.

Table 5.

Preparation administered	Example 8	Example 9	Example 10
AUC_W 0 →72 hr (count · hr · ml^{-1})	3988	5482	5618
AUC_G 0 →31 hr (ng · hr · ml^{-1})	19.9	54.5	76.7

<EXAMPLE 11>

To a buffer solution containing G-CSF, a buffer solution containing D-mannitol and aminoalkylmethacrylate copolymer E (Eudragit E100) was

added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
Eudragit E100	7.5% (w/w)
D-mannitol	75.0% (w/w)
Buffer components	appropriate amounts
Total	100 % (w/w)

<COMPARATIVE EXAMPLE 3>

To a buffer solution containing G-CSF, a buffer solution containing D-mannitol was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
D-mannitol	81.8% (w/w)
Buffer components	appropriate amounts
Total	100 % (w/w)

<EXPERIMENTAL EXAMPLE 6>

Male beagles were used in this experiment. The preparations from Example 11 and Comparative Example 3 were separately packed in gelatin capsules such that each capsule would give the dog 50 μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal

cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood G-CSF levels were determined by ELISA. Table 6 shows the values of area under the blood G-CSF level us time curve (AUC_G) for the preparations tested. As a result, it was found that Eudragit E100 remarkably promotes the adsorption of G-CSF through nasal mucosa.

Table 6.

Preparation administered	Example 11	Comparative Ex. 3
AUC_G 0 $\rightarrow$31 hr ($ng \cdot hr \cdot ml^{-1}$)	67.1	16.4

<EXAMPLE 12>

To a buffer solution containing insulin, a buffer solution containing sucrose, aminoalkylmethacrylate copolymer E (Eudragit E100) and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Insulin	18% (w/w)
Eudragit E100	27% (w/w)
HPMC	9% (w/w)
Sucrose	32% (w/w)
Buffer components	appropriate amounts

Total	100% (w/w)

<EXAMPLE 13>

To a buffer solution containing insulin, a buffer solution containing sucrose, poly-L-arginine and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Insulin	18% (w/w)
Poly-L-arginine	27% (w/w)
HPMC	9% (w/w)
Sucrose	32% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 14>

To a buffer solution containing insulin, a buffer solution containing sucrose, diethylaminoethyl (DEAE)-dextran and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Insulin	18% (w/w)
DEAE-dextran	27% (w/w)
HPMC	9% (w/w)
Sucrose	32% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 15>

To a buffer solution containing insulin, a buffer solution containing sucrose, chitosan and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Insulin	18% (w/w)
Chitosan	27% (w/w)
HPMC	9% (w/w)
Sucrose	32% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 4>

To a buffer solution containing insulin, a buffer solution containing sucrose and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Insulin	18% (w/w)
HPMC	9% (w/w)
Sucrose	60% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 5>

The insulin (as described above) was dissolved in a buffer solution to prepare a liquid preparation for subcutaneous administration having the following concentration.

Insulin	1.0 mg/ml

<EXPERIMENTAL EXAMPLE 7>

The preparations from Examples 12-15 and Comparative Example 4 were administered to male beagles through the nose; and the preparation from Comparative Example 5 was administered to male beagles subcutaneously. For the pernasal administration group, individual preparations were packed in gelatin capsules such that each capsule would give the dog 70 μg of insulin per kg of body weight. The gelatine capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. In the subcutaneous administration group, the preparation from Comparative Example 5 was administered subcutaneously to the back of each dog such that 25 μg of insulin was administered per kg of body weight. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood insulin levels were determined by ELISA. Table 7 shows the value of area under the blood insulin level vs time

curve (AUC) for each preparation. As a result, it was found that Eudragit E100 remarkably promotes the pernasal absorption of insulin. Further, its absorption promoting effect was superior to the effect of poly-L-arginine, DEAE-dextran and chitosan. The bioavailability of the insulin in the preparation of Example 12 was 27% as for the subcutaneous administration of insulin.

Table 7.

Preparation administered	Example 12	Comparative Example 4	Comparative Example 5
AUC 0 →7 hr ($ng \cdot hr \cdot ml^{-1}$)	29.0	2.6	38.8

Preparation administered	Example 13	Example 14	Example 15
AUC 0 →7 hr ($ng \cdot hr \cdot ml^{-1}$)	2.9	2.5	23.6

<EXAMPLE 16>

To a buffer solution containing G-CSF, a buffer solution containing D-mannitol and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
Eudragit E100	7.5% (w/w)
D-mannitol	75.2% (w/w)
Buffer components	appropriate amounts

Total	100% (w/w)

<EXAMPLE 17>

To a buffer solution containing G-CSF, a buffer solution containing D-mannitol and poly-L-arginine was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
Poly-L-arginine	7.5% (w/w)
D-mannitol	75.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 18>

To a buffer solution containing G-CSF, a buffer solution containing D-mannitol and diethylaminoethyl (DEAE)-dextran was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
DEAE-dextran	7.5% (w/w)
D-mannitol	75.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 19>

To a buffer solution containing G-CSF, a buffer

solution containing D-mannitol and chitosan was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

G-CSF	10.0% (w/w)
Chitosan	7.5% (w/w)
D-mannitol	75.2% (w/w)
Buffer components	appropriate amounts
Total	100 % (w/w)

<EXPERIMENTAL EXAMPLE 8>

Male beagles were used in this experiment. The preparations from Examples 16, 17, 18 and 19 were separately packed in gelatin capsules such that each capsule would give the dog 50 μg of G-CSF per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood G-CSF levels were determined by ELISA. Table 8 shows the values of area under the blood G-CSF level vs time curve (AUC_G) for the preparations tested. As a result, it was found that the powder preparation containing Eudragit E100 exhibits the highest AUC_G value. From the above, it

became evident that the absorption promoting effect of Eudragit E100 is superior to that of the other polycations, i.e. poly-L-arginine, DEAE-dextran and chitosan.

Table 8.

Preparation administered	Example 16	Example 17
AUC_G 0 →31 hr ($ng \cdot hr \cdot ml^{-1}$)	46.4	35.7
Preparation administered	**Example 18**	**Example 19**
AUC_G 0 →31 hr ($ng \cdot hr \cdot ml^{-1}$)	22.9	42.8

<EXAMPLE 20>

To a buffer solution containing erythropoietin, a buffer solution containing sucrose, aminoalkylmethacrylate copolymer E (Eudragit E100) and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Erythropoietin	30% (w/w)
Eudragit E100	30% (w/w)
HPMC	10% (w/w)
Sucrose	15% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 6>

To a buffer solution containing erythropoietin, a buffer solution containing sucrose and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Erythropoietin	30% (w/w)
HPMC	10% (w/w)
Sucrose	45% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 21>

To a buffer solution containing erythropoietin, a buffer solution containing sucrose, poly-L-arginine and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Erythropoietin	30% (w/w)
Poly-L-arginine	30% (w/w)
HPMC	10% (w/w)
Sucrose	15% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 22>

To a buffer solution containing erythropoietin, a buffer solution containing sucrose, diethylaminoethyl

(DEAE)-dextran and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Erythropoietin	30% (w/w)
DEAE-dextran	30% (w/w)
HPMC	10% (w/w)
Sucrose	15% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 23>

To a buffer solution containing erythropoietin, a buffer solution containing sucrose, chitosan and hydroxypropylmethyl cellulose (HPMC) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Erythropoietin	30% (w/w)
Chitosan	30% (w/w)
HPMC	10% (w/w)
Sucrose	15% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 7>

Erythropoietin was dissolved in a buffer solution to prepare a liquid preparation for subcutaneous administration having the following concentration.

Erythropoietin 250 μg/ml

<EXPERIMENTAL EXAMPLE 9>

The preparations from Examples 20-23 and Comparative Example 6 were administered to male beagles through the nose; and the preparation from Comparative Example 7 was administered to male beagles subcutaneously. For the pernasal administration group, individual preparations were packed in gelatin capsules such that each capsule would give the dog 120 μg of erythropoietin per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. In the subcutaneous administration group, the preparation from Comparative Example 7 was administered subcutaneously to the back of each dog such that 5 μg of erythropoietin was administered per kg of body weight. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood erythropoietin levels were determined by ELISA. Table 9 shows the value of area under the blood erythropoietin level vs time curve (AUC) for each preparation. As a result, it was found that Eudragit E100 remarkably promotes the pernasal absorption of erythropoietin. Further, its absorption promoting

effect was superior to the effect of poly-L-arginine, DEAE-dextran and chitosan. The bioavailability of the erythropoietin in the preparation of Example 20 was 15% relative as for the subcutaneous administration of erythropoietin.

Table 9.

Preparation administered	Example 20	Comparative Example 6	Example 21
AUC 0 → 11 hr ($U \cdot hr \cdot ml^{-1}$)	29.1	1.5	19.1

Preparation administered	Example 22	Example 23	Comparative Example 7
AUC 0 → 11 hr ($U \cdot hr \cdot ml^{-1}$)	6.6	20.2	7.9

(1 μg of erythropoietin is equivalent to 130 U.)

<EXAMPLE 24>

To a buffer solution containing growth hormone, a buffer solution containing D-mannitol and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Growth hormone	10.0% (w/w)
Eudragit E100	7.5% (w/w)
D-mannitol	75.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 8>

To a buffer solution containing growth hormone, a buffer solution containing D-mannitol was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the following formula.

Growth hormone	10.0% (w/w)
D-mannitol	82.7% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXPERIMENTAL EXAMPLE 10>

Male beagles were used in this experiment. The preparations from Example 24 and Comparative Example 8 were separately packed in gelatin capsules such that each capsule would give the dog 50 μg of growth hormone per kg of body weight. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation. After the administration, blood samples were taken from the forearm vein at regular intervals. Blood growth hormone levels were determined by ELISA. Table 10 shows the values of area under the blood growth hormone level vs time curve (AUC) for the preparations tested.

As a result, it was found that Eudragit E100 remarkably promotes the pernasal absorption of growth hormone. The absorption ratio for the case where Eudragit E100 was added was 10 times higher than the ratio for the absence of Eudragit E100.

Table 10.

Preparation administered	Example 24	Comparative Ex. 8
AUC 0 $\rightarrow$11 hr ($ng \cdot hr \cdot ml^{-1}$)	13.0	1.3

<EXAMPLE 25>

To a buffer solution containing influenza A antigen, a buffer solution containing D-mannitol and aminoalkylmethacrylate copolymer E (Eudragit E100) was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the formula below. It should be noted here that the percent by weight of influenza A antigen mentioned below is a value including the buffer components contained in the relevant reagent.

Influenza A antigen	4.0% (w/w)
Eudragit E100	7.5% (w/w)
D-mannitol	81.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<COMPARATIVE EXAMPLE 9>

To a buffer solution containing influenza A

antigen, a buffer solution containing D-mannitol was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the formula below. It should be noted here that the percent by weight of influenza A antigen mentioned below is a value including the buffer components contained in the relevant reagent.

Influenza A antigen	4.0% (w/w)
D-mannitol	88.7% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 26>

To a buffer solution containing influenza A antigen, a buffer solution containing D-mannitol and poly-L-arginine was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the formula below. It should be noted here that the percent by weight of influenza A antigen mentioned below is a value including the buffer components contained in the relevant reagent.

Influenza A antigen	4.0% (w/w)
Poly-L-arginine	7.5% (w/w)
D-mannitol	81.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 27>

To a buffer solution containing influenza A antigen, a buffer solution containing D-mannitol and diethylaminoethyl (DEAE)-dextran was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the formula below. It should be noted here that the percent by weight of influenza A antigen mentioned below is a value including the buffer components contained in the relevant reagent.

Influenza A antigen	4.0% (w/w)
DEAE-dextran	7.5% (w/w)
D-mannitol	81.2% (w/w)
Buffer components	appropriate amounts
Total	100% (w/w)

<EXAMPLE 28>

To a buffer solution containing influenza A antigen, a buffer solution containing D-mannitol and chitosan was added. The resultant mixture was spray-dried to thereby obtain a powder form preparation for pernasal administration having the formula below. It should be noted here that the percent by weight of influenza A antigen mentioned below is a value including the buffer components contained in the relevant reagent.

Influenza A antigen	4.0% (w/w)
Chitosan	7.5% (w/w)
D-mannitol	81.2% (w/w)
Buffer components	appropriate amounts

Total 100% (w/w)

<EXPERIMENTAL EXAMPLE 11>

<<Day 1 of the Experiment (1st Administration)>>

Blood samples were taken from the forearm vein of beagles to be used in the experiment. The preparations from Examples 25-28 and Comparative Example 9 were packed separately in gelatin capsules such that 24 μl of influenza A antigen would be administered per one capsule. The gelatin capsule was mounted in Publizer™ (Ishikawa Seisakusho) having a silicone tube about 5.0 cm in length bonded to its tip. Then, the silicone tube portion was inserted into the nasal cavity of each dog through one of the nostrils, followed by pressing the rubber ball portion of the Publizer™ to administer the preparation.

<<Day 15 of the Experiment (2nd Administration)>>

The preparations from Examples 25-28 and Comparative Example 9 were administered to the beagles through the nose. The grouping of the dogs, the dose and the method of administration were the same as for day 1 of the experiment.

<<Day 29 of the Experiment>>

Blood samples were taken from the forearm vein of the beagles administered with influenza A antigen.

<<Determination of the Amounts of Antibodies>>

The amounts of anti-influenza A antibodies in the sera collected on days 1 and 29 were determined by ELISA. The amounts of antibodies of the two subclasses, IgG1 and IgG2, were determined. Changes in the amounts of anti-influenza A antibodies based on their amounts on day 1 were compared. The amounts of anti-influenza A antibodies were compared as difference in absorbance between wells immobilizing the relevant antigen and wells not immobilizing the antigen. Tables 11 and 12 show the ratios of those individuals on day 29 in which anti-influenza A antibodies were induced (number of dogs: 4 in each group). As a result, it was found that both anti-influenza A-IgG1 and anti-influenza A-IgG2 are most frequently induced in the Eudragit E100-added group. From the above, it became evident that Eudragit E100 is useful as an adjuvant for pernasal vaccines and that the effect thereof is superior to the effect of the other polycations, i.e. poly-L-arginine, DEAE-dextran and chitosan.

Table 11. Anti-Influenza A-IgG1 Antibody Induction Ratio

Preparation administered	Example 25	Comparative Example 9	Example 26
Day 29 (after two sensitizations)	50%	0%	25%

Preparation administered	Example 27	Example 28
Day 29 (after two		

sensitizations)	0%	50%

Table 12. Anti-Influenza A-IgG2 Antibody Induction Ratio

Preparation administered	Example 25	Comparative Example 9	Example 26
Day 29 (after two sensitizations)	100%	25%	100%

Preparation administered	Example 27	Example 28
Day 29 (after two sensitizations)	25%	25%

Industrial Applicability

By adding a cationic polymer (in particular, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate) or a cationic polymer plus a viscous polymer to a medicine of high molecular weight for producing a preparation in powder form, it is possible to achieve effective absorption of the medicine of high molecular weight through mucosa.

All of the publications, patents and patent applications cited in the present specification are incorporated herein by reference in their entirety.

CLAIMS

1. A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer.

2. The preparation of claim 1, further comprising a viscous polymer.

3. The preparation of claim 1, wherein the cationic polymer is a copolymer of aminoalkylmethacrylate.

4. The preparation of claim 1, wherein the cationic polymer is polyvinyl acetal diethylaminoacetate.

5. The preparation of claim 1, wherein the cationic polymer is poly-L-arginine.

6. The preparation of claim 2, wherein the viscous polymer is hydroxypropylmethyl cellulose.

7. The preparation of claim 1, wherein the medicine of high molecular weight is selected from the group consisting of bioactive peptides and proteins, antibodies, vaccines, and antigens.

8. The preparation of claim 7, wherein the bioactive peptide is a granulocyte colony-stimulating factor.

9. The preparation of any one of claims 1-8, which is a preparation for pernasal administration.

10. A pharmaceutical composition in powder form, comprising a medicine of high molecular weight and a cationic polymer.

11. The pharmaceutical composition of claim 10, wherein the medicine of high molecular weight is selected from the group consisting of bioactive peptides and proteins, antibodies, vaccines, and antigens.

12. The pharmaceutical composition of claim 11, wherein the medicine of high molecular weight is selected from the group consisting of insulin, erythropoietin, growth hormone, and influenza antigens.

ABSTRACT

A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed.

By adding a cationic polymer (in particular, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate) or a cationic polymer plus a viscous polymer to a medicine of high molecular weight for producing a preparation in powder form, it is possible to achieve effective absorption of the medicine of high molecular weight through mucosa.

Attorney's Docket No.:_____

DECLARATION, POWER OF ATTORNEY AND PETITION

I (We), the undersigned inventor(s), hereby declare that:
My residence, post office address and citizenship are as stated below next to my name, I (We) believe that I am (we are) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled
HIGH MOLECULAR WEIGHT MEDICINE-CONTAINING PREPARATION IN POWDER FORM FOR ADMINISTRATION THROUGH MUCOSA
the specification of which

- ☐ is attached hereto.
- ☐ was filed on _____as
  Application Serial No. _____
  and amended on _____.
- ■ was filed as PCT international application
  Number PCT/JP99/03563
  on July 1, 1999,
  and was amended under PCT Article 19
  on_____(if applicable).

I (We) hereby state that I (We) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I (We) do not know and do not believe that this invention was ever known or used before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States for more than one year prior to this application; that this invention or discovery has not been patented or made the subject of an inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months before this application.

I (We) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

I (We) hereby claim foreign priority benefits under Section 119(a)-(d) of Title 35 United States Code, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application No.	Country	Filing date	Priority claimed
192722/1998	Japan	July 8, 1998	■ Yes ☐ No
81549/1999	Japan	March 25, 1999	■ Yes ☐ No
			☐ Yes ☐ No
			☐ Yes ☐ No

I hereby claim the benefit under Section 119(e) of Title 35 United States Code, of any United States application(s) listed below.

_____ _____

(Application Number) (Filing Date)

_____ _____

(Application Number) (Filing Date)

I (We) hereby claim the benefit under Section 120 of Title 35 United States Code, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Section 112 of Title 35 United States Code, I (We) acknowledge the duty to disclose material information as defined in Section 1.56(a) of Title 37 Code of Federal Regulations, which occurred between the filing date of the prior application and national or PCT international filing date of this application:

Yosuke UEKI

NAME OF SECOND JOINT INVENTOR

Yosuke Ueki

Signature of Inventor

December 12, 2000

Date

Residence: Gunma, Japan

Citizen of: Japan

Post Office Address:

c/o Iyaku Kaihatsu Kenkyusho,
Kirin Beer Kabushiki Kaisha,
3, Miyaharamachi, Takasaki-shi,
~~Gunma,~~ 370-1295 Japan

Application Serial No.	Filing Date	Status (pending, patented, abandoned)

And I (We) hereby appoint: Stephen A. Bent, Registration No. 29,768; David A. Blumenthal, Registration No. 26,257; John J. Feldhaus, Registration No. ~~28,822~~; Donald D. Jeffery, Registration No. 19,980; Peter G. Mack, Registration No. ~~26,001~~; Brian J. McNamara, Registration No. 32,789; Sybil Meloy, Registration No. ~~22,749~~; Colin G. Sandercock, Registration No. 31,298; Bernhard D. Saxe, Registration No. ~~28,665~~; Richard L. Schwaab, Registration No. 25,479; and Arthur Schwartz, Registration No. 22,115.

I(We) hereby request that all correspondence regarding this application be sent to the firm of FOLEY & LARDNER whose Post office address is: Washington Harbour, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 U.S.A.

I (We) declare further that all statements made herein of my (our) knowledge are true and that all statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Hideaki NOMURA
NAME OF FIRST SOLE INVENTOR

Residence: Gunma, Japan

Hideaki Nomura
Signature of Inventor

Citizen of: Japan

December 12, 2000
Date

Post Office Address:
c/o Iyaku Kaihatsu Kenkyusho,
Kirin Beer Kabushiki Kaisha,
3, Miyaharamachi, Takasaki-shi,
Gunma, 370-1295 Japan

SEQUENCE LISTING

<110> KIRIN-AMGEN INC.

<120> High molecular weight medicine-containing preparation in powder form for administration through mucosa

<130>

<140> PCT/JP99/03563
<141> 1999-07-01

<150> JP 10-192722
<151> 1998-07-08

<150> JP 11-81549
<151> 1999-03-25

<160> 3

<210> 1
<211> 175
<212> PRT

<400> 1

Met	Thr	Pro	Leu	GlY	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
-1	+1			5					10						15
Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu

20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His

65 70 75

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile

80 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser

145 150 155

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro

160 165 170

<210> 2

<211> 174

<212> PRT

<213> Homo sapiens

<400> 2

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys

1 5 10 15

Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln
20 25 30
Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val
35 40 45
Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys
50 55 60
Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser
65 70 75 80
Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser
85 90 95
Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp
100 105 110
Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro
115 120 125
Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe
130 135 140
Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe
145 150 155 160
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
165 170

<210> 3
<211> 175
<212> PRT

<400> 3
Met Ala Pro Thr Tyr Arg Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
-1 +1 5 10 15

Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu

20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His

65 70 75

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile

80 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser

145 150 155

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro

160 165 170